Full-Time

Senior Associate Accounting

Posted on 4/25/2025

Amgen

Amgen

10,001+ employees

Develops biologic therapies for serious illnesses

Compensation Overview

$77.4k - $95k/yr

+ Bonus + Stock-based long-term incentives

Mid, Senior

Tampa, FL, USA + 1 more

More locations: Thousand Oaks, CA, USA

This position is hybrid, requiring some in-office presence, but the exact number of in-office days is not specified.

Category
Financial Accounting
Tax Accounting
Management Accounting
Accounting
Requirements
  • Master’s degree
  • Bachelor’s degree and 2 years of accounting experience
  • Associate’s degree and 6 years of accounting experience
  • High school diploma / GED and 8 years of accounting experience
Responsibilities
  • Be responsible for accurate, complete, and timely periodic accounting close for specific ELMAC countries.
  • Support the preparation of close packages (including variance analysis), and disclosure checklist.
  • Operate as a link between local, regional, and functional finance teams to establish clear roles & responsibilities and install the appropriate processes and tools.
  • Support and advise local Finance Leads with Tax compliance, internal and external audits as well as the implementation of recommended improvements.
  • Create and track financial metrics for management.
  • Provide ad hoc support to local Finance Leads and flag all opportunities and challenges.
  • Keep track of the effectiveness of SLAs, process maps, and SOPs, and monitor the various Finance functions.
Desired Qualifications
  • Bachelor’s degree or equivalent (an emphasis in Accounting is desirable).
  • 3+ years of related professional experience.
  • Proficiency in technical knowledge of accounting (US GAAP), accounting processes and ERP systems.
  • Basic knowledge of indirect taxation
  • Excellent communication (both verbal and written) skills, including the ability to interact with Amgen middle management effectively and confidentially.
  • Spanish language oral and written.
  • Excellent and insightful analytical skills; ability to drive meaningful insights from large datasets.
  • Being able to demonstrate a high level of professionalism.

Amgen develops medicines aimed at treating serious illnesses, focusing on biotechnology. The company researches, develops, and sells biologic therapies, which are medicines made from living organisms. These therapies target conditions like cancer, cardiovascular diseases, and autoimmune disorders. Amgen's approach involves a strong commitment to research and development, allowing them to create new treatments and maintain a pipeline of potential therapies. Unlike many competitors, Amgen emphasizes biologic therapies and reinvests a large portion of its earnings back into R&D. The goal of Amgen is to improve patient care by providing effective treatments for serious health conditions.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Simplify Jobs

Simplify's Take

What believers are saying

  • Acquisition of Micromet boosts Amgen's oncology portfolio with BiTE antibody blinatumomab.
  • Institutional investments indicate strong confidence in Amgen's financial health and prospects.
  • Amgen's AI-driven drug discovery investments could accelerate R&D capabilities.

What critics are saying

  • Micromet acquisition may face clinical or regulatory challenges impacting strategic goals.
  • Investor pressure for short-term gains may affect long-term R&D investments.
  • FTC scrutiny on mergers could hinder Amgen's future strategic growth.

What makes Amgen unique

  • Amgen focuses on biologic therapies derived from living organisms.
  • The company has a strong pipeline in oncology, cardiovascular, and autoimmune disorders.
  • Amgen's strategic acquisitions enhance its innovative medicine portfolio.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Amgen
Jun 2nd, 2025
Amgen to Acquire Micromet| Amgen

The acquisition includes blinatumomab, a Bispecific T cell Engager (BiTE) antibody in Phase 2 clinical development for acute lymphoblastic leukemia (ALL). Blinatumomab is also in clinical development for the treatment of non-Hodgkin's lymphoma (NHL), and could have applications in other hematologic malignancies.

MarketBeat
Jan 28th, 2024
Factory Mutual Insurance Co. Makes New Investment in Amgen Inc. (NASDAQ:AMGN)

Factory Mutual Insurance Co. purchased a new position in Amgen Inc. (NASDAQ:AMGN - Free Report) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 53,500 shares of the medical research company's stock, valued at approxim

The Quantum Insider
Jan 16th, 2024
Honeywell Announces the Closing of $300 Million Equity Investment Round for Quantinuum at $5 Billion Pre-Money Valuation

JPMorgan Chase has one of the world's most highly regarded specialist teams working on quantum technologies within the financial services industry and has been working with Quantinuum and its predecessor companies since 2020.

ETF Daily News
Dec 17th, 2023
Northwest Quadrant Wealth Management LLC Invests $237,000 in Amgen Inc. (NASDAQ:AMGN)

Northwest Quadrant Wealth Management LLC bought a new position in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 883 shares of the medical research company’s stock, valued at approximately $237,000. A number of other institutional investors […]

Horizon Therapeutics
Sep 21st, 2023
Rule 2.7 Announcement: Amgen Inc to Acquire Horizon Therapeutics plc | Horizon Therapeutics plc

The Investor Relations website contains information about Horizon Therapeutics plc's business for stockholders, potential investors, and financial analysts.

INACTIVE